Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats

Journal of Peptide Science

Volumn 10, Issue 9, 2004, Pages 535-545

  Matsui, Toshiro ^a   Imamura, Miho ^a   Oka, Hiromi ^a   Osajima, Katsuhiro ^b   Kimoto, Ko Ichi ^c   Kawasaki, Terukazu ^d   Matsumoto, Kiyoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Senmi Ekisu Co   (Japan)

^c TOKYO KASEI UNIVERSITY   (Japan)

^d KYUSHU SANGYO UNIVERSITY   (Japan)

Author keywords

Angiotensin I converting enzyme; Antihypertensive peptide; Hypertension; Renin angiotensin system; Tissue accumulation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; DIPEPTIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; VALYLTYROSINE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HEART; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MALE; MEAN RESIDENCE TIME; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIPEPTIDES; HYPERTENSION; RATS; RATS, INBRED SHR; TISSUE DISTRIBUTION;

EID: 4544295137     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.568     Document Type: Article

References (22)

1. Kawasaki T, Seki E, Osajima K, Yoshida M, Asada K, Matsui T, Osajima Y. Antihypertensive effect of valyltyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J Human Hypertens 2000; 14: 519-523.
2. Matsui T, Li C-H, Tanaka T, Maki T, Osajima Y, Matsumoto K. Depressor effect of wheat germ hydrolysate and its novel angiotensin I-converting enzyme inhibitory peptide, Ile-Val-Tyr, and the metabolism in rats and human plasma. Biol Pharm Bull 2000; 23: 427-431.
3. Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 1996; 126: 3063-3068.
4. Matsui T, Tamaya K, Seki E, Osajima K, Matsumoto K, Kawasaki T. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin Exp Pharm Physiol 2002; 29: 204-208.
5. Matsui T, Tamaya K, Seki E, Osajima K, Matsumoto K, Kawasaki T. Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. Biol Pharm Bull 2002; 25: 1228-1230.
6. Matsui T, Hayashi A, Tamaya K, Matsumoto K, Kawasaki T, Murakami K, Kimoto K. Depressor effect induced by dipeptide, Val-Tyr in hypertensive transgenic mice is in part due to the suppression of human circulating renin-angiotensin system. Clin Exp Pharm Physiol 2003; 30: 262-265.
7. Johnston CI, Burrell LM, Perich R, Jandeleit K, Jachson B. The tissue renin-angiotensin system and its functional role. Clin Exp Pharm Phys 1992; 19(Suppl. 19): 1-5.
8. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme. In Hypertension, Laragh JH, Brenner BM (eds). Raven Press: New York, 1995; 1217-1231.
9. Horiuchi M, Fujimura K, Terashima T, Iso T. Method for determination of angiotensin-converting enzyme activity in blood and tissue by high-performance liquid chromatography. J Chromatogr 1982; 233: 123-130.
10. Matsui T, Tamaya K, Kawasaki T, Osajima Y. Determination of angiotensin metabolites in human plasma by fluorimetric high-performance liquid chromatography using a heart-cut column-switching technique. J Chromatogr B 1999; 729: 89-95.
11. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982; 220: 63-69.
12. Jarrott B, Drummer O, Hooper R, Anderson A, Miach P, Louis W. Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects. Am J Cardiol 1982; 49: 1547-1549.
13. Jankowski A, Skorek A, Krzysko K, Zarzycki PK, Ochocka RJ, Lamparczyk H. Captopril: determination in blood and pharmacokinetics after single oral dose. J Pharm Biomed Anal 1995; 13: 655-660.
14. Sakakibara Y, Takami Y, Zwieb C, Nakayama T, Suiko M, Nakajima H, Liu MC. Purification, characterization, and molecular cloning of a novel rat liver dopa/lyrosine sulfotransferase. J Biol Chem 1995; 270: 30 470-30 478.
15. Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T, Miyazaki M. Pathogenic role of vascular angiotensin converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharm Physiol 1991; 18: 649-659.
16. Chai SY, Perich R, Jackson B, Mendelsohn AO, Johnston CI. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. Clin Exp Pharm Physiol 1992; 19: (suppl. 19): 7-12.
17. Jackson B, Cubela RB, Johnston CI. Inhibition of tissue angiotensin converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J Pharmacol Exp Ther 1988; 245: 950-955.
18. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases. Hypertension 2001; 38: 1382-1387.
19. Weiss D, Kools JJ, Taylor R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-454.
20. Shiota N, Miyazaki M, Okunishi H. Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 1992; 20: 168-174.
21. Nishijo N, Takamine S, Sugiyama F, Kimoto K, Taniguchi K, Horiguchi H, Ogata T, Murakami K, Fukamizu A, Yagami K. Vascular remodeling in hypertensive transgenic mice. Exp Anim 1999; 48: 203-208.
22. Marsden PA, Brenner BM, Ballermann BJ. Mechanism of angiotensin action on vascular smooth muscle, the adrenal and the kidney. In Hypertension, Laragh JH, Brenner BM (eds). Raven Press: New York, 1995; 1247-1271.